Discovery of WS-157 as a highly potent, selective and orally active EGFR inhibitor

EGFR tyrosine kinase inhibitor (EGFR-TKI) has been used successfully in clinic for the treatment of solid tumors. In the present study, we reported the discovery of WS-157 from our in-house diverse compound library, which was validated to be a potent and selective EGFR-TKI. WS-157 showed excellent i...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Pengxing, Niu, Shenghui, Wang, Shuai, Shi, Xiaojing, Feng, Siqi, Du, Linna, Zhang, Xuyang, Ma, Zhilu, Yu, Bin, Liu, Hongmin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6900553/
https://www.ncbi.nlm.nih.gov/pubmed/31867165
http://dx.doi.org/10.1016/j.apsb.2019.06.010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6900553/
https://www.ncbi.nlm.nih.gov/pubmed/31867165
http://dx.doi.org/10.1016/j.apsb.2019.06.010

Ejemplares similares